|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
MERCK SHARP & DOHME INTERNATIONAL
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
bradycardia |
|
tachycardia |
|
Asthenia |
|
dizziness |
|
dry mouth |
|
fatigue |
|
hot flashes |
|
nausea and/or vomiting |
|
somnolence |
|
Arthralgia |
|
central nervous system (CNS) effects |
|
agitation |
|
anxiety |
|
confusion |
|
depression |
|
irritability |
|
eye problems |
|
blurred vision |
|
dry eyes |
|
eye irritation |
|
chills |
|
constipation |
|
diarrhea |
|
dyspepsia |
|
dysphagia |
|
euphoria |
|
flatulence |
|
heat sensitivity |
|
hypertension |
|
increased sweating |
|
increased thirst |
|
insomnia |
|
muscle or joint stiffness, tightness, or rigidity |
|
muscle pain or spasms |
|
polyuria |
|
pruritus |
|
tinnitus |
|
tremor |
|
vertigo |
|
warm and/or cold sensations |
|
Chest pain, severe |
|
dyspnea |
|
heaviness, tightness, or pressure in chest and/or neck |
|
palpitations |
|
paresthesias |
|
Arrhythmia |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Coronary artery disease, predisposition to |
|
>> Hepatic function impairment, moderate |
|
>> Renal function impairment, severe |
|
|
ADULT DOSE:
|
|
Antimigraine agent-
Oral, 5 or 10 mg (base) as a single dose .
If necessary, additional doses may be taken at intervals of at least two hours . |
|
MAXIMUM ADULT DOSE:
|
|
30 mg in twenty-four hours .
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established in children up to 18 years of age .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Antimigraine agent-
Oral, 5 or 10 mg (base) as a single dose .
If necessary, additional doses may be taken at intervals of at least two hours . |
|
|
|
|
|